scholarly journals Comparison of Efficacy and Safety of Rosuvastatin, Atorvastatin and Pravastatin among Dyslipidemic Diabetic Patients

2013 ◽  
Vol 2013 ◽  
pp. 1-7 ◽  
Author(s):  
Lolwa Barakat ◽  
Amin Jayyousi ◽  
Abdulbari Bener ◽  
Bilal Zuby ◽  
Mahmoud Zirie
Keyword(s):  
Renal Function ◽  
Electronic Medical Records ◽  
Medical Records ◽  
Large Scale ◽  
Population Based ◽  
Diabetic Patients ◽  
Population Based Study ◽  
Number Of Patients ◽  
Second Year ◽  
New Onset

Objectives. To investigate the efficacy and the safety of the three most commonly prescribed statins (rosuvastatin, atorvastatin, and pravastatin) for managing dyslipidemia among diabetic patients in Qatar. Subjects and Methods. This retrospective observational population-based study included 350 consecutive diabetes patients who were diagnosed with dyslipidemia and prescribed any of the indicated statins between September 2005 and September 2009. Data was collected by review of the Pharmacy Database, the Electronic Medical Records Database (EMR viewer), and the Patient's Medical Records. Comparisons of lipid profile measurements at baseline and at first- and second-year intervals were taken. Results. Rosuvastatin (10 mg) was the most effective at reducing LDL-C (29.03%). Atorvastatin reduced LDL-C the most at a dose of 40 mg (22.8%), and pravastatin reduced LDL-C the most at a dose of 20 mg (20.3%). All three statins were safe in relation to muscular and hepatic functions. In relation to renal function, atorvastatin was the safest statin as it resulted in the least number of patients at the end of 2 years of treatment with the new onset of microalbuminuria (10.9%) followed by rosuvastatin (14.3%) and then pravastatin (26.6%). Conclusion. In the Qatari context, the most effective statin at reducing LDL-C was rosuvastatin 10 mg. Atorvastatin was the safest statin in relation to renal function. Future large-scale prospective studies are needed to confirm these results.

scholarly journals Validation of fragility fractures in primary care electronic medical records: A population-based study

2019 ◽  
Vol 15 (5) ◽  
pp. e1-e4 ◽  
Author(s):  
Daniel Martinez-Laguna ◽  
Alberto Soria-Castro ◽  
Cristina Carbonell-Abella ◽  
Pilar Orozco-López ◽  
Pilar Estrada-Laza ◽  
...  
Keyword(s):  
Primary Care ◽  
Electronic Medical Records ◽  
Medical Records ◽  
Fragility Fractures ◽  
Population Based ◽  
Population Based Study

scholarly journals Thirty-Day Mortality and Morbidity in COVID-19 Positive vs. COVID-19 Negative Individuals and vs. Individuals Tested for Influenza A/B: A Population-Based Study

2020 ◽  
Vol 7 ◽  
Author(s):  
Vardan Nersesjan ◽  
Moshgan Amiri ◽  
Hanne K. Christensen ◽  
Michael E. Benros ◽  
Daniel Kondziella
Keyword(s):  
Mortality Rate ◽  
Influenza A ◽  
Large Scale ◽  
Fold Increase ◽  
Population Based ◽  
Test Results ◽  
Population Based Study ◽  
Mortality And Morbidity ◽  
Aggregated Data ◽  
New Onset

Background: As of October 2020, COVID-19 has caused 1,000,000 deaths worldwide. However, large-scale studies of COVID-19 mortality and new-onset comorbidity compared to individuals tested negative for COVID-19 and individuals tested for influenza A/B are lacking. We investigated COVID-19 30-day mortality and new-onset comorbidity compared to individuals with negative COVID-19 test results and individuals tested for influenza A/B.Methods and findings: This population-based cohort study utilized electronic health records covering roughly half (n = 2,647,229) of Denmark's population, with nationwide linkage of microbiology test results and death records. All individuals ≥18 years tested for COVID-19 and individuals tested for influenza A/B were followed from 11/2017 to 06/2020. Main outcome was 30-day mortality after a test for either COVID-19 or influenza. Secondary outcomes were major comorbidity diagnoses 30-days after the test for either COVID-19 or influenza A/B. In total, 224,639 individuals were tested for COVID-19. To enhance comparability, we stratified the population for in- and outpatient status at the time of testing. Among inpatients positive for COVID-19, 356 of 1,657 (21%) died within 30 days, which was a 3.0 to 3.1-fold increased 30-day mortality rate, when compared to influenza and COVID-19-negative inpatients (all p < 0.001). For outpatients, 128 of 6,263 (2%) COVID-19-positive patients died within 30 days, which was a 5.5 to 6.9-fold increased mortality rate compared to individuals tested negative for COVID-19 or individuals tested positive or negative for influenza, respectively (all p < 0.001). Compared to hospitalized patients with influenza A/B, new-onset ischemic stroke, diabetes and nephropathy occurred more frequently in inpatients with COVID-19 (all p < 0.05).Conclusions: In this population-based study comparing COVID-19 positive with COVID-19 negative individuals and individuals tested for influenza, COVID-19 was associated with increased rates of major systemic and vascular comorbidity and substantially higher mortality. Results should be interpreted with caution because of differences in test strategies for COVID-19 and influenza, use of aggregated data, the limited 30-day follow-up and the possibility for changing mortality rates as the pandemic unfolds. However, the true COVID-19 mortality may even be higher than the stated 3.0 to 5.5-fold increase, owing to more extensive testing for COVID-19.

scholarly journals Validation of fragility fractures in primary care electronic medical records: A population-based study

2019 ◽  
Vol 15 (5) ◽  
pp. e1-e4
Author(s):  
Daniel Martinez-Laguna ◽  
Alberto Soria-Castro ◽  
Cristina Carbonell-Abella ◽  
Pilar Orozco-López ◽  
Pilar Estrada-Laza ◽  
...  
Keyword(s):  
Primary Care ◽  
Electronic Medical Records ◽  
Medical Records ◽  
Fragility Fractures ◽  
Population Based ◽  
Population Based Study

scholarly journals 30-day mortality and morbidity in COVID-19 versus influenza: A populationbased study

2020 ◽  
Author(s):  
Vardan Nersesjan ◽  
Moshgan Amiri ◽  
Hanne Krarup Christensen ◽  
Michael E. Benros ◽  
Daniel Kondziella
Keyword(s):  
Mortality Rate ◽  
Influenza A ◽  
Large Scale ◽  
Fold Increase ◽  
Population Based ◽  
Test Results ◽  
Population Based Study ◽  
Mortality And Morbidity ◽  
Vascular Comorbidity ◽  
New Onset

Background As of July 2020, COVID-19 has caused 500,000 deaths worldwide. However, large-scale studies of COVID-19 mortality and new-onset comorbidity compared to influenza and individuals tested negative for COVID-19 are lacking. We aimed to investigate COVID-19 30-day mortality and newonset comorbidity compared to individuals with negative COVID-19 test results and individuals tested for influenza. Methods and findings This population-based cohort study utilized electronic health records covering roughly half (n=2,647,229) of Denmark's population, with nationwide linkage of microbiology test results and death records. All individuals ≥18 years tested for COVID-19 and individuals tested for influenza were followed from November 1, 2017 to June 30, 2020. The main outcome was 30-day mortality after a test for either COVID-19 or influenza. Secondary outcomes were major comorbidity diagnoses 30-days after the test for either COVID-19 or influenza. In total, 224,639 individuals were tested for COVID-19. Among inpatients positive for COVID-19, 356 of 1657 (21%) died within 30 days, which was a 3.0 to 3.1-fold increased 30-day mortality rate, when compared to influenza and COVID-19-negative inpatients (all p<0.001). For outpatients, 128 of 6,263 (2%) COVID-19-positive patients died within 30 days, which was a 5.5 to 6.9-fold increased mortality rate compared to influenza and COVID-19-negative patients, respectively (all p<0.001). Compared to hospitalized patients with influenza, new-onset ischemic stroke, diabetes and nephropathy occurred more frequently in inpatients with COVID-19 (all p<0.05). Conclusions In this population-based study comparing COVID-19 with influenza, COVID-19 was associated with increased rates of major systemic and vascular comorbidity and substantially higher mortality, which is likely even higher than the stated 3.0 to 5.5-fold increase owing to more extensive testing for COVID-19.

scholarly journals No Evidence For An Association Between Renal Function And Bleeding Events In Patients On Coumarin Therapy: A Population-Based Study

2017 ◽  
Vol 20 (9) ◽  
pp. A601
Author(s):  
E Houben ◽  
E Smits ◽  
JA Overbeek ◽  
RM Herings ◽  
MP Van Herk-Sukel ◽  
...  
Keyword(s):  
Renal Function ◽  
Population Based ◽  
Bleeding Events ◽  
Population Based Study
Sign in / Sign up

Export Citation Format

Share Document